ClinicalTrials.gg
RecruitingNCT04010604Updated Sep 23, 2019

A Registered Cohort Study on SMA

An observational study in Spinal Muscular Atrophy, sponsored by Wan-Jin Chen. Recruiting at 1 site in China. Open to participants aged 1 Week to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-23.

Sponsored by Wan-Jin Chen · Observational

How we know

From the registry’s dates

  • Started Jul 2019; still recruiting 7 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Ages
1 Week to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Muscular Atrophy, Spinal with a site in China — 6 open to participants now, 13 under way, 4 of them phase 3. Muscular Atrophy, Spinal · China.

Started
2019
the only one that year
Observational
7 of 23
2 open now
Primary completion
2039-12
later than 12 of 12 live
Registered
3rd of 23
by date

Among the 23 studies in Muscular Atrophy, Spinal with a site in China, this one is the only one that started in 2019, is one of 7 observational ones, reaches primary completion later than 12 of the 12 other live ones, and was the 3rd registered.

Muscular Atrophy, Spinal

282 studies on the registry are indexed under Muscular Atrophy, Spinal; 71 are open to participants now.

Browse Muscular Atrophy, Spinal studies →

Open to participants now

6 of the 23 studies in Muscular Atrophy, Spinal with a site in China are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 56 Muscular Atrophy, Spinal studies recruiting now, 28 (50%) set no upper age limit and 25 (45%) stop at 75 or younger; 44 take children under 18; 11 take healthy volunteers.

This study: 1 Week to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Muscular Atrophy, Spinal with a site in China, or all of them as a file.
02

Study summary

Spinal muscular atrophy (SMA) is an autosomal recessive disease that causes progressive muscle wasting and weakness due to loss of motor neurons in the spinal cord. This is a registered cohort of spinal muscular atrophy (SMA) type I,II and III in China. This study will provide further insights into the clinical course of SMA including overall survival, demographic characteristics, motor function, respiratory support, feeding and nutritional support, growth and development. The correlation of genotype and phenotype will be conducted.

03

Conditions studied

  • Spinal Muscular Atrophy
04

Who can participate

Ages eligible
1 Week to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

SMA patients are diagnosed with SMN1 gene deletion or mutation.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with SMA types I, II and III
  • Asymptomatic SMA carriers
  • Relatives of SMA patients or carriers
  • Unrelated healthy controls
  • Participants or Parent(s)/legal guardian(s) willing and able to complete the process

Exclusion criteria

Exclusion Criteria:

* Participants are unable to comply with trial procedures and visit schedule

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • SMA type I
  • SMA type II
  • SMA type III
  • Asymptomatic carriers of SMA
  • Relatives of SMA patients and carriers
  • Unrelated healthy controls
06

What researchers measure

Primary outcomes

  1. The time to death

    Time frame: From date of enrollment until the date of death from any cause, assessed up to 20years

  2. The correlation of genotype and phenotype

    Genotype is defined by survival motor neuron (SMN) 2 copy number(s) and phenotype is defined by clinical types and characteristics.

    Time frame: From date of enrollment until the date of death from any cause, assessed up to 20years

07

Study locations

1 of 1 sites recruiting
  • Department of Neurology, First Affiliated Hospital Fujian Medical University
    Fuzhou, Fujian 350005, China
    Recruiting
    • Wan-Jin Chen, PhD · Contactwanjinchen75@fjmu.edu.cn · 86-0591-87982772
    • Wan-Jin Chen, MD,PhD · Principal investigator
    • Ning Wang, MD, PhD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2019 (actual). Primary completion is estimated for Dec 2039, 245 months after the start.

Of 58 observational studies under Muscular Atrophy, Spinal, half reached primary completion within 88 months of starting (the median), counting those still running; a quarter within 36. This study's planned 245 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2019
First posted
Jul 8, 2019
StartActual
Jul 1, 2019
Primary completionEst.
Dec 31, 2039
CompletionEst.
Dec 31, 2049
Last update
Sep 23, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04010604
Lead sponsor
Wan-Jin Chen
Responsible party
Wan-Jin Chen (The Vice-Director for the Department of Neurology, First Affiliated Hospital of Fujian Medical University) — Sponsor-investigator
First posted
Jul 8, 2019
Start date
Jul 1, 2019
Primary completion
Dec 31, 2039 (estimated)
Completion
Dec 31, 2049 (estimated)
Last update
Sep 23, 2019

Study contacts

Yi Lin, PhD
Contact
linyi7811@163.com
86-0591-87982772
Wan-Jian Chen, PhD
Contact
wanjinchen75@fjmu.edu.cn
86-0591-87982772

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion